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ReviewThe impact of ERa action on muscle metabolism
and insulin sensitivity e Strong enough for
a man, made for a womanAndrea L. Hevener*, Zhenqi Zhou, Timothy M. Moore, Brian G. Drew, Vicent RibasABSTRACT
Background: The incidence of chronic disease is elevated in women after menopause. Natural variation in muscle expression of the estrogen
receptor (ER)a is inversely associated with plasma insulin and adiposity. Moreover, reduced muscle ERa expression levels are observed in
women and animals presenting clinical features of the metabolic syndrome (MetSyn). Considering that metabolic dysfunction impacts nearly a
quarter of the U.S. adult population and elevates chronic disease risk including type 2 diabetes, heart disease, and certain cancers, treatment
strategies to combat metabolic dysfunction and associated pathologies are desperately needed.
Scope of the review: This review will provide evidence supporting a critical and protective role for skeletal muscle ERa in the regulation of
metabolic homeostasis and insulin sensitivity, and propose novel ERa targets involved in the maintenance of metabolic health.
Major conclusions: Studies identifying ERa-regulated pathways essential for disease prevention will lay the important foundation for the
rational design of novel therapeutics to improve the metabolic health of women while limiting secondary complications that have plagued
traditional hormone replacement interventions.
 2018 Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords Estrogen action; Estrogen receptors; Insulin sensitivity; Metabolic homeostasis1. INTRODUCTION
For over two decades researchers have shown strong relationships
between estrogen action and metabolic health in women. Moreover,
epidemiological reports indicate that chronic disease incidence in-
creases in women following menopause. Considering that menopause
occurs on average by age 51 (National Institutes of Health, NIA www.
nia.nih.gov), and that life expectancy has increased for white females
tow80.6 years (The National Vital Statistics Report, 2012), women in
the modern era are challenged with heightened disease risk associated
with increasing adiposity and metabolic dysfunction for up to three
decades of life. Although many researchers and clinicians have
focused on the impact of replacement estrogens to ameliorate clinical
symptoms and provide protective health benefit, an incomplete un-
derstanding of hormone action as well as estrogen receptor distribu-
tion and function has contributed to our continued confusion and failure
to advance therapeutic strategies to combat chronic disease-
associated pathologies for women.
Regarding the benefits of exogenous hormone replacement therapy
(HRT) on diabetes risk after menopause, large randomized clinical
trials of postmenopausal estrogen-based HRT compared with placebo
as well as prospective cohort studies, have shown reductions in fasting
glucose, insulin, and incidence of new onset T2D [1e6]. Meta-
analyses indicate a 30% lower relative risk [RR 0.7 (CI, 0.6e0.9)] ofDepartment of Medicine, Division of Endocrinology, Diabetes and Hypertension, David
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with placebo [7]. The mechanism by which HRT reduces T2D incidence
in postmenopausal women is not yet known however molecular
studies in rodents indicate that this protective effect may be achieved
in part as a consequence of estrogen-induced insulin-sensitization.
Considering that 75e85% of insulin-stimulated glucose disposal is
into skeletal muscle and since skeletal muscle typically represents
30e40% of total body mass, we have focused our efforts in under-
standing the effects of estradiol/ERa action in this tissue.
In this review, we will present studies related to the biological actions
of estrogen receptors in skeletal muscle in controlling glucose ho-
meostasis and insulin sensitivity, as insulin resistance and metabolic
dysfunction are identified as major underpinnings involved in the
pathobiology of chronic diseases that plague our society today. We will
present basic research suggesting that the estrogen receptor (ER) a
form ERa (encoded by the gene ESR1) is an important target to combat
metabolic dysfunction.
2. ER LIGAND-MEDIATED EFFECTS ON METABOLISM AND
INSULIN ACTION
Identification and phylogenetic analysis of steroid receptors in basal
vertebrates and reconstruction of the sequences and functional attri-
butes of ancestral proteins led to the conclusion that the first steroidGeffen School of Medicine, University of California, Los Angeles, CA, 90095, USA
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receptor was an estrogen receptor [8]. Early studies in reproductive
tissues investigating the actions of estradiol led to the paradigm of
classical nuclear ERs as ligand-activated transcription factors [9].
Although ERs exist in two main forms, a and b, which have multiple
splice variants of unknown function, ERs exhibit tissue specificity in
expression and function [10]. The classical, or genomic mechanism of
ER action, describes a scenario whereby the ligand-activated ER dis-
sociates from its chaperone and binds as a dimer either directly to
estrogen response elements (ERE) in target genes promoters or indi-
rectly to AP-1 or SP-1 response elements through protein tethering
association with other DNA-bound transcription factors [11,12]
(Figure 1). Following DNA binding, ER dimers interact with basal
transcription factors leading to activation or repression of target gene
expression. Overlap in binding sites for E2-liganded ERa and ERb is
observed when receptors are expressed individually; however, when
both ERs are present, few sites are shared. Each ER restricts the binding
site occupancy of the other, with ERa typically dominating [13]. More-
over, ligand-activated ERs promote transcription in a cyclic fashion. The
repeated cycling of the receptor complex on and off target promoters in
the presence of continuous E2 stimulation may represent a mechanism
of continuous sensing and adaptation to the external hormonal milieu to
yield the appropriate transcriptional response [14].
In addition to classical signaling, E2-ERa can act within seconds to
minutes via extranuclear and membrane-associated forms of the re-
ceptor [15] (Figure 1). Membrane associated receptors localize to
caveolae where they congregate with other signaling molecules,
including G proteins, growth factor receptors, tyrosine kinases (Src),
linker proteins (MNAR), and orphan G-protein coupled receptors
(GPCRs) [16]. In a variety of cell types, membrane and extranuclear
pools of ERs activate protein kinases that phosphorylate transcription
factors to promote their nuclear translocation and transcriptional action
[15,17]. The G protein-coupled estrogen receptor (GPER), or GPR30,
has been reported to respond to E2; however, its role as an ER is still
controversial. Although emerging evidence in murine muscle cells
shows diverse distribution of GPR30 in the nucleus, mitochondria, and
cytoplasm [18], functional aspects of this receptor in vivo remain
unclear; thus, GPR30 will not be discussed in this review.Figure 1: Molecular actions of ERa to activate or repress target genes by classica
response element in target gene promoters; P, phosphorylation; TF, transcription factor.
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nuclear ligand-activated transcription factors with respect to their
reproductive actions, the role of nuclear vs. extranuclear actions of ERs
in the regulation of metabolism and insulin action remains contro-
versial and inadequately interrogated [19]. More recently, an emerging
theme in the field is that for many targets, nuclear and non-nuclear
signaling must collaborate to achieve the full biological action of
estradiol [20]. Although non-genomic signaling is supported for spe-
cific cell types under defined conditions, scientific dissection of these
pathways remains challenging, thus a central question in the field
pertaining to the tissue-specific sites of action and the molecular
mechanisms by which ERa selectively activates or represses target
genes remains.
Reduced whole body ERa expression or impaired ERa function due to
genetic alteration (including genetic variants) has been linked with
increased prevalence of specific features of the metabolic syndrome
including insulin resistance and obesity in both male and female hu-
man subjects and rodents [21e28]. Since obesity is a prominent
phenotype observed in estrogen or ERa deficient rodent models, the
specific role of ERa in adipocytes and the phenotypic outcomes of
obesity as a consequence of adipose-specific ERa deletion in mice is
currently under investigation by several laboratories around the world.
Whether the obesity phenotype observed in whole body Esr1/ mice
or women harboring an ESR1 polymorphisms is explained by impaired
ERa action in adipose tissue specifically, or as a secondary phenotype
of ERa impairment in other metabolic tissues requires resolution.
Insulin resistance is a central disorder in the pathogenesis of obesity
and type 2 diabetes and is a defining feature of the Metabolic Syn-
drome, a clustering of metabolic abnormalities including obesity, hy-
pertension, glucose intolerance, and dyslipidemia [29,30]. Metabolic
dysfunction and a clustering of these abnormalities is worrisome as
this clinical distinction is now thought to impact nearly a quarter of the
US population and drive increased risk of numerous chronic disease
states including diabetes, cardiovascular disease, neurodegeneration,
and certain forms of cancer [31,32]. Normally cycling pre-menopausal
women show enhanced insulin sensitivity compared to men when
sensitivity is normalized to lean mass (since women have a reducedl DNA binding, non ERE genomic action, or non-genomic actions. ERE, Estrogen
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 21
Reviewlean body mass compared to men) [33]. Improved insulin sensitivity
and protection against factors promoting insulin resistance are likely
underpinnings of reduced type 2 diabetes incidence observed for pre-
menopausal women compared with men [33,34]. Case-in-point,
although a 40e50% reduction in insulin-mediated glucose disposal
is consistently observed in males following high fat feeding [35,36], E2-
replete females, humans and rodents, are typically protected against a
high fat diet and acute fatty acid-induced insulin resistance [37,38].
In contrast to the metabolic protection seen in normally cycling pre-
menopausal women, following menopause (biological or surgically-
induced), a precipitous decline in insulin sensitivity coincides with a
dramatic increase in fat mass, and elevated circulating inflammatory
markers, LDL, triglycerides, and fatty acids [176]. Similar to humans,
ovariectomy (OVX) mice and rats become insulin resistant, show
impaired exercise-stimulated glucose disposal into muscle [39], and
are more susceptible to the deleterious effects of high fat diet or lipid
oversupply. The physiological consequences of OVX are prevented by
treatment with an ERa-specific agonist or by restoration of circulating
estradiol within a physiological concentration [40e42].
Although chronic administration of E2 is shown to improve insulin
sensitivity in rodents, the acute action of E2 to promote insulin-
stimulated glucose uptake into muscle remains disputed; this
despite consistent observations of E2-induced activation of Akt and
AMP-activated Protein Kinase (AMPK) [42,43]. Furthermore, although
administration of intravenous conjugated estrogens and E2 to post-
menopausal women or OVX rats, respectively, elicited a significant
increase in glucose disposal during hyperinsulinemic-euglycemic
clamp studies [44,45], ex vivo treatment of skeletal muscle with E2
failed to recapitulate the same increase in insulin-stimulated glucose
disposal [43]. It could be that methodological issues have clouded this
relationship since only super-physiological insulin concentrations have
been tested thus far, potentially masking the true effects of estradiol on
insulin action at physiological insulin doses. This ex vivo observation by
Rogers et al. [43] is also in contrast to short-term estradiol effects on
insulin action in myotubes from postmenopausal women and age-
matched men [46]. Additionally, recent research by Park et al.
shows that the timing of E2 administration following menopause may
also be of importance given the reduced nuclear expression of ERa
found in muscle from women >10 years from final menstrual period
(FMP) late postmenopausal (LPM), versus early postmenopausal (EPM)
women <6 years from FMP (EPM). Moreover, in parallel with a lack of
E2 effect to improve insulin sensitivity in LPM, E2 failed to increase the
phosphorylation of AMPK and induce Pgc1a expression unlike EPM
[44,47]. Collectively, these data suggest that there could be a critical
window of therapeutic opportunity in which E2 administration could be
utilized for improving metabolic health and that the expression and
functionality of ERa may be a key determinant of therapeutic efficacy
[44,47].
Similar to findings for ovarian failure in women and rodents, a
reduction in circulating estrogens resulting from rare inactivating
mutations of the Cyp19 (aromatase) or experimental deletion in Cyp19
in mice confers an obesity-insulin resistance phenotype [21,48e55].
The physiological and genetic evidence argues that E2 and ER favor
insulin sensitivity in rodents and humans of both sexes when E2 is
maintained within a tight physiological concentration. Indeed,
replacement or augmentation of E2 to supraphysiological levels or
over-stimulation of ERs is thought to induce insulin resistance sec-
ondary to hyperinsulinemia and or a reduction in total GLUT4
expression in muscle [56,57]. In fact, two studies have reported that in
postmenopausal women, higher plasma levels of E2 were prospec-
tively associated with increased risk of developing T2D [58,59].22 MOLECULAR METABOLISM 15 (2018) 20e34  2018 Published by Elsevier GmbH. This isClearly, additional studies in rodents and humans using a dose
response strategy are necessary to better understand the interplay of
steroid hormones including E2, testosterone and progesterone on the
regulation of metabolism and insulin action in glucoregulatory tissues.
Thus, many questions remain: does E2 enhance skeletal muscle insulin
sensitivity and at what minimal pharmacological dose, and what are
the critical tissues of E2 action that confer protection against nutrient-
induced insulin resistance?
3. ESTROGEN RECEPTOR a e STRUCTURE AND GENOMIC
ACTION
The cellular effects of estrogens are mediated by two ERs: ESR1 (the
gene that encodes ERa) and ESR2 (ERb). ESR1 was identified in 1958
[60], and ESR2 was first identified in the rat prostate and ovary in 1996
[61]. Different splice variants of each receptor have been identified and
each exhibit distinct tissue expression patterns and functions [10,62].
With the exception of the ERaD3 isoform, all other ERs are composed
of six functional domains, from A to F, containing an NH2-terminal
domain (NTD), DNA-binding domain (DBD), and COOH-terminal
ligand-binding domain (LBD) (Figure 2). Two regions, named activa-
tion function (AF) have been identified as crucial for the transcriptional
response of the ERs; the first is localized at the NTD, and the second is
in the LBD [63]. ESR1 and ESR2 are structurally different in the ligand
binding pockets, and this knowledge was responsible for driving the
development of receptor-specific selective ligands [62], since ERs
primarily act as ligand-mediated transcriptional factors [9,62,64,65].
Although ERs were the first of the nuclear superfamily to be cloned
over two decades ago [66], the tissue-specific gene targets and
mechanisms of action, including activation and repression of genes
involved in the integrative regulation of metabolic health, remains an
area of intense investigation.
Since ERa is a ligand-dependent transcription factor that regulates a
large number of genes in diverse target tissues to achieve selective
action, the question arises as to how ERa exerts such specific and
exacting control over so many different processes. The interplay be-
tween ligand, receptor, DNA sequence, cofactors, chromatin context,
and post-translational modifications collectively govern transcriptional
regulation by ERa. As stated above, ERa can bind directly to DNA
(classical pathway) or can impact gene transcription indirectly via
proteineprotein tethering. In the classical sense, ERa homodimers are
thought to bind specific sequence motifs called estrogen response
elements (ERE) (Figure 2). The ERE is a 15bp palindrome consisting of
two PuGGTA half site separated by a 3bp spacer [67e69] and was first
identified in 1986 in the promoter of the Xenopus vitellogenin gene.
Interestingly, there are over 70,000 EREs present in the human
genome and 9944 EREs in the mouse genome. In total, 660 evolu-
tionarily conserved elements have been identified [70]. However, in
silico studies suggest that ERa binding is dependent on more factors
than just DNA sequence.
The chromatin structure and binding accessibility of ERa target sites
remains inadequately understood, but is currently under intense
investigation (Figure 3). It is estimated that only 23% of E2 responsive
genes are direct ERa targets [69]. Using ChIP-PET analysis in MCF-7
cells, Lin et al. identified 1,234 high confidence binding clusters of
which 94% were projected to be bona fide ERa binding regions [69].
Of importance, only 5% of the mapped estrogen receptor binding
sites were located within 5 kb upstream of the transcriptional start
sites of adjacent genes (regions containing the proximal promoters);
therefore, the vast majority of ERa binding sites mapped to intronic or
distal locations (>5 kb from 50 and 30 ends of adjacent transcript),an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 2: ERa structure (A) and DNA binding at an estrogen response element (ERE) (B) (adapted from [170]).
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Figure 3: Schematic showing potential mechanism(s) by which enhancer elements cooperate to regulate putative ERa target genes (A), and a cartoon showing a crosslinked
chromatin complex immunoprecipitated by a specific transcription factor of interest, herein ERa (adapted from [78,171,172]).
Reviewsuggesting transcriptional regulatory mechanisms act over signifi-
cant physical distances [69,71,72]. Of all the identified sites, 71%
harbored putative full estrogen response elements (EREs), 25% ERE
half sites, and 4% had no recognizable ERE sequences [69]. Of
important consideration, Lin et al. found that only ~20% of the bona
fide human ERa binding sites overlapped with whole genome
vertebrate alignments suggesting limited conservation of functional
ERa binding sites between species [69]. Thus, since most studies
interrogating ERa binding on a genome-wide scale are performed in
breast cancer cell lines, species, sex, and cell-type specific dynamics
of estrogen action should be deliberated.
Classical genetics approaches provide evidence of redundant, additive,
and synergistic enhancer relationships over a variety of loci. More
recent studies, using a multiplex interference approach (in Isikawa and
T-47D cells), have revealed strong collaboration between predominant
and supportive ERa binding sites exposing a complex functional hi-
erarchy of enhancers regulating the expression of ERa target genes
[72]. Current thinking is that chromosomal looping allows for the
collaborative action of these distal sites and that distance to the target
gene and strength of the ERE motif predict the ERa binding site
importance [72]. At least in liver, ERE sites, ERE half sites, AP1, bHLH,
ETS, and Forkhead-binding motifs were enriched DNA sequences in24 MOLECULAR METABOLISM 15 (2018) 20e34  2018 Published by Elsevier GmbH. This isERa binding regions [73]. Considering that most of what we know
about ERa action is gleaned from MCF7 cells, an important question is
whether the genomics of ERa in breast cancer can be translated to
muscle and other metabolic tissues [74]. Now that we are moving
beyond whole genome binding site cartography, putative ERa binding
sites will require validation by functional interrogation using muta-
genesis and chromatin immunoprecipitation approaches in a cell
specific context [71,72,75e78].
4. THE ROLE OF ERa IN REGULATING INSULIN ACTION AND
GLUCOSE DISPOSAL
ESR1 is broadly expressed in the central nervous system and in pe-
ripheral tissues including adipose, skeletal muscle, liver, and immune
cells [79]. Women and men as well as male and female mice carrying
specific ESR1 variants develop features of the metabolic syndrome
including obesity, glucose intolerance, and insulin resistance. Clinical
evidence is undeniable; the clustering of these metabolic abnormalities
increases disease risk (heart disease, type 2 diabetes, and certain
forms of cancer) [21,22,80,81]. Of translational relevance, whole body
ERa knockout mice (ERaKO) recapitulate the metabolic dysfunction
observed in a male human subject with a rare inactivating receptoran open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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mutation, as well as aspects of the phenotypes observed in subjects
with genetic polymorphisms in the receptor [21,22,80]. Not only do
ERaKO mice have increased adiposity caused by reductions in energy
expenditure, but they also exhibit glucose intolerance and insulin
resistance, thus demonstrating the critical role for ESR1 in regulating
energy and metabolic homeostasis [80e82]. The integration of central
and peripheral ESR1 action as well as the interaction of ERa and sex
chromosome action remains to be defined; however, the tissue
dissection approach to studying ERa using mice with conditional
deletion alleles has allowed the research community the opportunity to
delineate unique aspects of ERa biology in a tissue and sex-specific
context.
Observational findings indicate that ESR1 expression levels are
reduced in muscle from women with the metabolic syndrome, and that
natural variation in muscle ESR1 expression in women is inversely
correlated with adiposity and fasting insulin, markers of metabolic
health (i.e. low muscle ESR1 expression levels are associated with
metabolic dysfunction and increased adiposity) [83]. Remarkably
similar findings were observed across numerous strains of inbred
female mice, as well as in genetically obese animals, thereby illus-
trating the strong relationship between muscle ERa expression and
metabolic health. Collectively, these data suggest that maintenance of
ERa expression or activation of muscle ESR1 could serve as an
effective means to combat diseases associated with metabolic
dysfunction [83]. Although these strong correlative findings suggest a
relationship between muscle ERa expression levels and metabolic
health, few studies have directly tested a causal relationship. Does a
loss of ERa specifically from myocytes drive skeletal muscle insulin
resistance, or does the insulin resistance phenotype observed in the
ERaKO model arise from increased adiposity/altered adipokine/Figure 4: The impact of whole body ERa deletion on
MOLECULAR METABOLISM 15 (2018) 20e34  2018 Published by Elsevier GmbH. This is an open access
www.molecularmetabolism.comcytokine secretion and impaired central drive of feeding and ambu-
latory movement?
Although two forms of the receptor are expressed in many of the
glucoregulatory tissues, ERa is expressed at much higher abundance
than ERb or GPR30, as these transcripts are nearly undetectable in
muscle from humans and rodents [46,83e85]. Consistent with these
observations, homozygous deletion of ERb failed to produce insulin
resistance [86] in contrast to the marked skeletal muscle insulin
resistance observed in ERaKO animals (Figure 4) [81,87]. The un-
derlying mechanism contributing to impaired insulin action in muscle
of ERaKO animals remains disputed. Findings reported by Bryzgalova
et al. [82] suggest reduced total GLUT4 levels in muscle as an un-
derlying cause for the ERaKO insulin resistance phenotype; however,
these findings were not supported by Ribas et al. [81]. Furthermore,
despite maintenance of GLUT4 mRNA and protein, Ribas et al. reported
more dramatic skeletal muscle insulin resistance in ERaKO mice than
Bryzgalova et al. Hevener and colleagues suggest that the skeletal
muscle insulin resistance observed in ERaKO mice is predominantly a
consequence of direct ERa deletion effects on insulin action with a
secondary impact of inflammation on proximal insulin signaling. This
hypothesis was later confirmed using muscle-conditional deletion al-
leles studied in vivo, ex vivo, and in vitro.
Indeed, in female muscle-specific ERa knockout mice and myotubes
with ERa knockdown, no alteration in GLUT4 mRNA or protein in
skeletal muscle was observed despite reduced insulin-stimulated
glucose disposal into muscle during clamp studies. Findings in the
muscle-specific ERa mouse are consistent with those of whole body
ERa mice [88]. Furthermore, additional studies by Barros et al. [57,89]
assessing GLUT4 expression in response to ovariectomy with/without
E2 supplementation are in conflict with other studies of similar designmetabolism and insulin action [80e82,173e175].
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Review[46,85,90e92]. Given the lack of consensus ERE in the GLUT4 pro-
moter [93] and absence of confirmatory findings in cellular reporter
and chromatin immunoprecipitation assays, the regulation of GLUT4
expression by ERa requires further investigation. GLUT4 is regulated
by several redundant transcriptional pathways [94,95]. Considering
that total GLUT 4 transcript and protein levels are not reduced in
humans or rodents in the context of insulin resistance, obesity, and
type 2 diabetes, or between men and women [96,97], it is likely that in
the absence of ERa, other transcription factors compensate to main-
tain GLUT4 levels [98e103]. This is not to say that ERa is not involved
in the exercise-stimulated increase in GLUT4 observed following
training [96,104,105], given the concomitant increase in ERa
expression observed in muscle of exercise-trained humans and mice
[84,106,107].
Myocyte enhancer factor 2 (MEF2) expression and a functional MEF2
element in the GLUT4 promoter are critical for GLUT4 gene expression
[108]. Furthermore, reciprocal regulation between ERa and MEF2 is
observed in cardiomyocytes via ERa interaction with class II HDAC in
female mice only [109]. Despite complex transcriptional signal inte-
gration in the regulation of GLUT4 expression [94,95,110e113], it is
conceivable that elevated ERa action could promote increased GLUT4
transcription via heightened protein tethering with MEF2 on the GLUT4
promoter or by indirect action via AMPK [43,114]. It is important to note
that transcriptional activity of the GLUT4 promoter is quite low under
basal conditions, and other ovarian hormones (e.g. progesterone) areFigure 5: The impact of skeletal muscle-specific ERa deletion on metabolism and
replication and impaired muscle oxidative metabolism, despite maintenance of mtDNA
hyperfused mitochondria in MERKO muscle. The morphological changes coupled with an
and impaired macroautophagy, both processes critical for mitochondrial turnover by mitoph
by increased ROS production, inflammation, and insulin resistance in skeletal muscle of
mitochondrial and metabolic health [83].
26 MOLECULAR METABOLISM 15 (2018) 20e34  2018 Published by Elsevier GmbH. This isshown to play an antagonistic role in the regulation of GLUT4
expression [39]. These issues as well as the dose of E2 administration
during interventional studies (presumably off-target effects of super-
physiological doses of E2 are deleterious to metabolism), the age and
hormone status of the human subjects and rodents (species and strain)
used are important considerations when interpreting the literature.
Considering the varying roles that muscle and adipose tissue play in
controlling whole body metabolic homeostasis, it is likely that the
interplay of transcriptional regulators of GLUT4 vary markedly between
tissues. Taken together, these data would suggest a potential role for
ERa as an enhancer of GLUT4 transcription in muscle under certain
conditions, but not necessarily obligatory in the direct regulation of
GLUT4 expression under basal conditions.
Collectively, work by Ribas et al. suggests that the skeletal muscle
insulin resistance observed in whole body ERaKO mice and animals
with a muscle-specific deletion of ERa is predominantly the result of
impaired insulin signal transduction (Figure 5) [88]. A role for ERa in
the regulation of proximal insulin signal transduction has been sug-
gested previously as E2 administration to insulin resistant rodents
increases insulin receptor substrate (IRS)-1 abundance and insulin-
stimulated tyrosine phosphorylation and as well as phosphorylation
of Akt at activation site Ser473 [87,115]. Akt serves many functions in
myocytes including ERa-induced regulation of myogenic differentiation
[116], suppression of muscle-atrophy ubiquitin ligases via FOXO1 in-
hibition [117], and induction of genes associated with myocellularinsulin sensitivity. Skeletal muscle-specific ERa deletion reduced mitochondrial DNA
copy number. Increased PKA and reduced calcineurin activity promoted elongated,
imbalanced PKA-calcineurin axis blunted mitochondrial fission signaling through DRP1
agy. Collectively, the retention of damaged mitochondria to the network was paralleled
MERKO mice. Findings implicate a critical role for ERa in the maintenance of muscle
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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proliferation [116,118e121]. In breast cancer cell lines, endothelial
cells, and cortical neurons, ERa-specific binding and activation of
PI3kinase as well as suppression of the tumor suppressor and PI3ki-
nase inhibitory protein, PTEN, is well-established [122e126]; how-
ever, studies on this direct interaction are limited in skeletal muscle.
Additionally, E2 acting via ERa is also shown to promote phosphory-
lation of p38 MAPK [127,128], and transduction of a signaling cascade
shown to enhance GLUT4 intrinsic activity and glucose uptake [129e
131]. Furthermore, ERa activation of Akt and MAPK pathways is
thought to underlie E2-mediated protection of muscle against age-
induced sarcopenia [132e138], exercise-induced muscle damage
[120,134,139,140], and myocyte apoptosis in the face of a variety of
cellular perturbations [141e144]. Thus, ERa stimulation of muscle
growth and insulin sensitivity via these pathways is reasonable to
posit.
5. ERa AND SKELETAL MUSCLE FATTY ACID METABOLISM
AND INFLAMMATION
Normally cycling pre-menopausal women are protected against acute
lipid-induced insulin resistance compared with estrogen-deficient
women and men [38,145]. Furthermore, muscle from premeno-
pausal women shows enhanced insulin sensitivity despite 47% higher
triglyceride content compared with age-matched men [97]. This
observation in women, is consistent with a reduced respiratory
quotient and greater reliance on fatty acids as a fuel source [146].
These data indicate interesting similarities between E2 replete women
and exercise trained subjects including elevated muscle ERa
expression [84,106,107], heightened insulin sensitivity [101],
elevated muscle lipid tolerance [147], and enhanced oxidative ca-
pacity [148,149]. Consistent with the reported effects of E2 on
metabolism, estrogen supplementation is shown to enhance lipid
oxidation in vivo in men during acute endurance exercise [150], and
palmitate oxidation in myotubes from male subjects ex vivo [46]. The
effect of E2 to increase the expression of fatty acid transport protein
FAT/CD36 and FABP as well as transcription factors and key enzymes
that regulate oxidative metabolism [90,96,151] likely underlie these
observations in male subjects. Moreover, E2 treatment reduced HFD-
induced insulin resistance in skeletal muscle by 50% (assessed by
hyperinsulinemic-euglycemic clamp) in an ERa-dependent manner
[87]. In addition, similar to exercise, E2 is shown to rapidly stimulate
AMPK phosphorylation in both muscle and myotubes in culture
[43,152]. AMPK is considered a central regulator of many cellular
processes including growth, mitochondrial biogenesis, and oxidative
metabolism [153,154]. Comparable to the effects of E2, the ERa-
selective agonist PPT stimulates AMPK phosphorylation in muscle of
ovariectomized female rats [42] while OVX or whole body ERa deletion
is associated with reduced skeletal muscle levels of phosphorylated
AMPK [81,155]. Recent evidence from Lipovka et al. shows that ERa
but not b directly binds the bg-subunit domain of AMPK a [156].
Muscle PPARa, PPARd, and UCP2 expression are also reduced in
whole body ERaKO mice suggesting that E2 acting via ERa is essential
in the regulation of a coordinated program regulating oxidative
metabolism. Interestingly, although the phenotype of impaired muscle
fatty oxidation was recapitulated in the muscle-specific ERaKO mice
(MERKO), no alteration in basal p-AMPK, PPARa, PPARd, or UCP2 was
observed [88], suggesting that these specific alterations in muscle
gene expression are secondary to the loss of ERa in other metabolic
tissues (e.g. CNS, adipose tissue, or liver).
The mechanistic link between the accumulation of lipid intermediates,
activation of inflammatory signaling cascades, and impaired insulinMOLECULAR METABOLISM 15 (2018) 20e34  2018 Published by Elsevier GmbH. This is an open access
www.molecularmetabolism.comaction is shown in myocytes and rodent muscle, and these factors are
observed concurrently in obese, type 2 diabetic subjects [157e160] as
well as in muscle from whole body and muscle-specific ERaKO mice
[81]. Bioactive lipid intermediates including diacylglycerol, DAG, and
ceramides are believed to activate stress kinases including IKKb, c-
Jun-N-terminal kinase (JNK), and certain nPKCs [158,161e163].
Indeed, muscle from normal chow-fed whole body ERaKO mice
showed heightened inflammatory signaling as reflected by markedly
increased JNK phosphorylation and TNFa transcript [81]. A similar
inflammatory profile was observed in muscle from female MERKO
mice [83]. Collectively, these data illustrate the essential role of ERa is
regulating fatty acid oxidation (FAO) and inflammation in muscle and
highlight the primary nature of ERa in the direct control of these
processes. The impact of pathway crosstalk and other cellular
signaling mechanisms engaged in altering FAO and inflammation in
the context of ERa deficiency, are not well fleshed out. In addition to
the action of ERa on enzymes involved in fatty acid transport and
processing, new evidence is emerging regarding the direct role of ERa
on oxidative metabolism via control over specific mitochondrial pro-
cesses (discussed in greater detail below) [83]. With respect to in-
flammatory signaling activation, beyond ERa de-repression of
selective inflammatory targets within the nucleus, it is likely that
mitochondrial ROS production, sarcoplasmic reticulum stress, and
proinflammatory lipid species are additional mediators of heightened
inflammation in muscle.
6. THE ROLE OF MUSCLE ERa IN THE REGULATION OF
MITOCHONDRIAL FUNCTION
Despite model differences in gene and protein expression, skeletal
muscle insulin resistance and bioactive lipid accumulation was sur-
prisingly similar between ERaKO and MERKO animals [81,83]. Tri-
acylglycerol, diacylglycerol, and ceramides were all elevated
significantly in muscle from female mice lacking ERa globally or
specifically in muscle [81,83]. Consistent with these observations,
oxygen consumption rates in C2C12 myotubes with ERa knockdown
(KD) were reduced significantly [83]. In addition, mitochondria from
muscle cells depleted of ERa produced high levels of reactive oxygen
species (ROS) thus promoting cellular oxidative stress. Analysis of
mitochondrial function confirmed a defect in respiratory complex 1
activity in MERKO muscle [83]. Moreover, mitochondria from MERKO
mice produced increased levels of H2O2 and superoxide, thus reca-
pitulating findings in C2C12 myotubes with Esr1-KD.
This defect in mitochondrial function was paralleled by a reduction in
expression of the only mammalian mitochondrial (mt) DNA polymerase,
Polg1, in both MERKO muscle as well as murine myotubes with Esr1
knockdown (Figure 5). Additionally, heavy water labeling of newly
synthesized mtDNA showed a reduction in the rate of mtDNA repli-
cation, functionally supporting an impact of the reduction in Polg1
expression in MERKO mouse muscle [83]. Additional mechanistic
studies showed that estradiol and ERa-selective ligand treatment
induced Polg1 expression in muscle cells; however, the ligand was
ineffective to induce gene expression when the receptor was absent.
Considering the presence of a consensus ERE in the Polg1 promoter,
ongoing studies in the Hevener laboratory will delineate the mecha-
nism(s) by which ERa regulates mtDNA replication via this polymerase.
mtDNA replication is intimately linked with mitochondrial remodeling
by a process known as fission [164]. The Hevener laboratory has
shown that treatment of murine myotubes with ERa agonists also
promotes this mitochondrial morphological alteration inducing the
severing of a mitochondrion into two daughter organelles achievedarticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 27
Reviewby high order dynamin related protein (Drp) 1 oligomers promoting
scission. Interestingly, although ERa activation drives mitochondrial
fission, it appears to achieve this shift in mitochondrial architecture
by a coordinated enzymatic regulation of the fission activator calci-
neurin and the calcineurin inhibitor Rcan1 [83]. Supporting the role of
ERa in the regulation of mitochondrial morphology, we observed that
mitochondria from both female and male MERKO mouse muscle
were enlarged, elongated, and hyperfused, suggesting a reduction in
fission:fusion dynamics.
Internally consistent with the morphological data obtained by trans-
mission electron microscopy, analysis of mitochondrial dynamics
signaling showed reduced fission signaling by Drp1 (including
increased phosphorylation at the inhibitory Ser637 site and reduced
total Drp1 protein on the outer mitochondrial membrane), as well as
increased abundance of the inner and outer mitochondrial membrane
fusion proteins OPA1 and Mfn2 [83] (Figure 5). Ribas et al. observed a
marked increase in expression of the mitochondrial fission inhibitor
Rcan1 in myotubes with Esr1-KD, female MERKO muscle, and muscle
from women displaying clinical features of the metabolic syndrome.
Ribas et al. overexpressed Rcan1 in myotubes using lentivirus and
showed that Rcan1 expression elevated to levels seen in MERKO
mouse muscle impaired insulin action [83]. Moreover, impairment in
muscle mitochondrial fission promoted dysfunction in mitochondrial
respiration and insulin action in primary mytobues from female mice
with Dnm1L deletion and in C2C12 myotubes with lentiviral-mediated
Dnm1L knockdown [83]. Therefore, we hypothesize that both a
reduction in the direct effects of ERa on insulin signaling as well as
indirect effects of ERa on insulin action mediated by mitochondrial
dysfunction contribute to the development of global disturbances in
metabolic health and insulin sensitivity (Figure 5).
In light of the observation that Rcan1 was only induced in female
MERKO muscle (not in males) despite a similar impairment in fissionFigure 6: Skeletal muscle-specific deletion of ERa reduces running performance, isometr
training e adapted from [83,166].
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initiated additional studies to flesh out the sex-specific mechanisms
that underlie altered mitochondrial dynamics and function in the
absence of ERa. These studies are viewed to be of translational
importance since it is well known that sex is an important biological
variable contributing to differences in disease incidence and mecha-
nisms of pathobiology.
Follow-up studies in the Hevener laboratory in MERKO mice, as well as
new studies in muscle-specific Polg1, Parkin (Park2), and Drp1
(Dnm1L) KOs, and mice with muscle-specific ERa overexpression, will
allow for the determination of whether the stall in mtDNA replication is
a primary defect driving mitochondrial dysfunction and insulin resis-
tance. Secondly, we will learn whether the impairment in mitochondrial
quality control and turnover seen in MERKO muscle is a consequence
or causal of the stall in mtDNA replication, and contributory or resultant
of insulin resistance. The use of broad transcriptomic, proteomic and
metabolomic approaches in rodents harboring conditional ERa deletion
alleles coupled with more targeted chromatin immunoprecipitation
analyses in ERa ligand treated animals will allow for the identification
of novel ERa target genes as well as reveal new mechanism(s) con-
trolling metabolic signaling nodes in insulin responsive tissues.
7. THE ROLE OF ERa IN THE REGULATION OF MUSCLE
PERFORMANCE AND EXERCISE TRAINING
In addition to the skeletal muscle-induced insulin resistance, MERKO
mice also fail to adapt to endurance training (Figure 6). Whether de-
fects in exercise training are linked with impaired mitochondrial
function and disruption of calcium homeostasis is unclear. In addition
to diminished muscular endurance in MERKO, Lai and Collins showed
that ERa deficient muscles are also fast fatiguing and have reduced
performance capability [165,166] (Figure 6). Studies from this groupic force contraction, and impairs specific molecular adaptations to endurance exercise
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
show that E2, in a concentration-dependent manner, elevates phos-
phorylation of the myosin regulatory light chain (pRLC) in C2C12
myotubes in culture and in muscles from C57BL/6J mice [166]. Fe-
male mice with a skeletal muscle-specific KO of ERa produced 16%
less eccentric and 16e26% less submaximal and maximal isometric
force with impaired force recovery relative to WT mice. Maximal torque
production by plantar- and dorsi-flexors were 16% and 12% lower in
female KO than WT mice, and produced 21e32% less power, and
submaximal isometric and peak concentric torques [166]. Data support
the hypothesis that ablation of ERa in skeletal muscle underlies muscle
weakness, suggesting that the beneficial effects of estradiol on muscle
strength are receptor mediated via ERa. Since metabolic function is
clearly linked with muscle quality and mass, and these traits are most
highly associated with morbidity and mortality in aging, strategies
aimed at maintaining muscle metabolism appear warranted especially
in women during the menopausal transition.
8. CONCLUSIONS AND PERSPECTIVES
In recent years, novel molecular targets have emerged offering the
prospect of pharmacological intervention to restore metabolic ho-
meostasis and insulin action, as well as ameliorate complications
associated with type 2 diabetes and obesity. The inherent beauty of
targeting ERa therapeutically is underscored by decades of research
and in depth knowledge related to biological/clinical efficacy and
toxicity profiles obtained for estradiol/SERMs during preclinical studies
in animal models and clinical trials in human subjects. Although es-
trogen treatment (primarily 17b-estradiol) is shown to promote energy
homeostasis, improve body fat distribution, and diminish insulin
resistance, b-cell dysfunction and inflammation, the challenge with
chronic hormone administration is the narrow therapeutic index. Thus,
the translation of the basic advances in diabetes and obesity treatment
described in this review, although successful in rodents, is problematic
when extending to clinical practice. However, ten years after the WHI
concluded that the risks of hormone therapy outweighed its benefits,
reevaluation of the WHI findings and determination that the risks of
breast cancer, coronary heart disease, stroke, and pulmonary embo-
lism with estrogen-progestin treatment were overstated, prompted a
position statement by the North American Menopause Society stating
that HRT has a role in short-term treatment of menopausal symptoms
[167]. Thus, considering the new and more positive light estradiol is
receiving by clinical experts, it will be important to determine whether
short-term treatment with a well-designed ERa agonist during early
menopause offers protection against metabolic dysfunction and insulin
resistance.
Additionally, it is imperative that we determine how to modulate the
specific ER-controlled pathways involved in energy balance and
glucose homeostasis and develop estradiol mimetics that initiate
specific cellular events promoting metabolic benefit without unwanted
side effects. This could possibly be achieved by fusion peptides
[168,169] or through the development of novel SERMs that retain the
beneficial metabolic effects of E2 in desired tissues including skeletal
muscle, while exerting antagonist action in breast and uterus. With
regard to whole body metabolism, obesity, and insulin sensitivity,
future studies should focus on identifying the critical nodes of ERa-
mediated metabolic crosstalk between all glucoregulatory tissues as
these integrative networks may reveal new pharmacological targets for
therapeutic exploitation.
Although this review focused on the role of ERa in controlling meta-
bolism and insulin action in skeletal muscle, clearly the expression of
ERa in other metabolic tissues contributes to specific aspects of globalMOLECULAR METABOLISM 15 (2018) 20e34  2018 Published by Elsevier GmbH. This is an open access
www.molecularmetabolism.commetabolism and metabolic health. Once the general phenotype of each
of the ERa deletion models is published, it will be important to inte-
grate the findings so that the field has a better perspective on the
tissue selective contribution of ERa to a phenotypic trait. Determination
of the overlapping and distinctive phenotypic traits of conditional ERa
deletion models will allow the field to better target ERa for global
impact. Since insulin resistance underlies most chronic diseases, the
Hevener laboratory has focused its efforts on understanding pathways
known to impair insulin action including inflammation, and organelle,
metabolic, and oxidative stress. Although collective evidence suggests
that ERa regulates a vast number of metabolic processes, emerging
findings suggest that ERa exerts a primary regulatory role on meta-
bolism by controlling specific aspects of mitochondrial function. Now
that novel technologies allow us to study this complex organelle in a
more precise and comprehensive way, a new era of mitochondrial
biology has emerged. A major area of focus for diabetes researchers is
to understand the genes that regulate key aspects of mitochondrial
function and determine how this organelle controls other pathways
including insulin action, inflammation, adiposity and muscle mass.
Lastly, a major limitation in our understanding and interpretation of E2-
ER action is the lack of information regarding the contribution of
extranuclear vs. nuclear ER actions, as well as ligand vs. non-ligand-
mediated functions of ERs in controlling key metabolic nodes in insulin
responsive tissues. Delineation of these pathways will be critical for
moving the field forward and advancing therapeutic strategies to
improve women’s health.
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